Phase
Condition
Eye Disease
Eye Disorders/infections
Vision Loss
Treatment
N/AClinical Study ID
Ages 30-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Presence of nuclear or cortical lens opacities in one/both eyes
Physician diagnosis of age related cataract
Good overall physical constitution
All participants must be follow the same regimen for surgery related medications, bothpre and post surgery. (Antibiotic, NSAID and Steroid eye drops)
Exclusion
Exclusion Criteria:
Subjects requiring Premium IOLs/multifocal implants
Advanced cataract
Severe Age-Related Macular Degeneration Presence or history of Glaucoma
Presence or history of Diabetes Mellitus
Any Retinal pathology - retinal detachment, retinitis pigmentosa, diabeticretinopathy, etc
Vision loss due to Central retinal artery occlusion or Central retinal vein occlusion
Vision loss due to presence of large pituitary tumors or aneurysms
Vision loss due to optic tract lesions
Vision loss due to bleeding into aqueous or vitreous chamber
Vision loss due to drug toxicity: Amiodarone, anti-tuberculosis drugs,hydroxychloroquine, tamoxifen
Major cardiovascular or cerebral events in the past 12 months
Allergy to fish oil or safflower oil
Pregnancy or lactation at any time during the study
Newly started or increased the dose of chronic systemic medication known to affecttear production including, but not limited to antihistamines, antidepressants,diuretics, corticosteroids or immunomodulators within 30 days of Screening or at anytime during the study
Participation in any other study involving an investigational drug or device withinthe past 30 days
Study Design
Connect with a study center
Cincinnati Eye Institute
Lexington, Kentucky 41017
United StatesActive - Recruiting
Southern Eye Associates
Greenville, South Carolina 29605
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.